Novartis Archives

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that could yield the company a new blockbuster. Now, the Swiss drug maker announced that its cardiovascular drug, canakinumab, was able to meet its primary endpoint in […]

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […]

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […]

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Apr 2017

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […]

April 19, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 18 Apr 2017

Two Big Pharma Players Team up to Take Over the NASH Space

Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis’ FXR agonist for NASH. After Allergan snapped up Tobira’s cenicriviroc (CVC) last year in a €1.4B deal, the company is now taking the next step to advance its pipeline in the Non-Alcoholic SteatoHepatitis (NASH) race. The pharma company is going […]

April 18, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 18 Apr 2017

The Top 12 Biotech Leaders You Should Know in Basel

After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your list of who’s who. Basel is home to some really big biotech and pharma companies and it’s consequently a cornerstone of the excellence Switzerland has demonstrated in the industry (also seen in Zurich). As a key […]

April 18, 2017 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […]

April 6, 2017 - 4 minutesmins - By External Contributor

News and Trends 24 Mar 2017

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […]

March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

Top 5 Biologicals from European Biopharma to Launch in 2017

A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novartis

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Novartis Negotiates its Way into the US Migraine Market

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

Two Big Pharma Players Team up to Take Over the NASH Space

The Top 12 Biotech Leaders You Should Know in Basel

How is Biotech Transforming Pharma’s R&D Model?

Novartis puts the Development of two Anti-Aging Drugs in American Hands

Top 5 Biologicals from European Biopharma to Launch in 2017

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!